The Centers for Medicare & Medicaid Services Aug. 15 released a state funding notice for the Cell and Gene Therapy Access Model. The CGT Access Model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative treatment and reduces health care expenditures. It will initially focus on gene therapies for sickle cell disease. The notice includes an opportunity for applicants to apply for cooperative agreement funding to support participation in the CGT Access Model. Applicants must apply for participation in the model through a state applications request and apply for funding through the state funding notice, both of which are due Feb. 28, 2025. The award date is anticipated for July 1, 2025. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Sept. 26 released guidance on state compliance with the Early and Periodic Screening, Diagnostic and Treatment…
Perspective
It’s an understatement to say everything on the national political scene is both unprecedented and unpredictable these days.To state the obvious, there will be…
Headline
The AHA July 25 urged the Centers for Medicare & Medicaid Services to maintain the uninsured rate at 8.7% under the inpatient prospective payment system…
Headline
The Department of Health and Human Services July 2 announced it will provide Medicaid and Children's Health Insurance Program coverage to incarcerated people…
Headline
The Medicaid and CHIP Payment and Access Commission (MACPAC) June 11 released its June report to Congress. The first chapter focuses on improving the…
Headline
A report released May 29 by the Government Accountability Office found a lack of state oversight on Medicaid managed care plans’ use of prior authorization for…